FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer

Lung Cancer

Volumn 89, Issue 2, 2015, Pages 115-120

  Kohutek, Zachary A ^a   Wu, Abraham J ^a   Zhang, Zhigang ^a   Foster, Amanda ^a   Din, Shaun U ^a   Yorke, Ellen D ^a   Downey, Robert ^a   Rosenzweig, Kenneth E ^b   Weber, Wolfgang A ^a   Rimner, Andreas ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Non small cell lung cancer; PET; Stereotactic body radiation therapy

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; COMPARATIVE STUDY; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; GLUCOSE METABOLISM; HUMAN; INTENSITY MODULATED RADIATION THERAPY; KAPLAN MEIER METHOD; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEREOTACTIC BODY RADIATION THERAPY; TUMOR VOLUME; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RADIOSURGERY; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOSURGERY; TREATMENT OUTCOME;

EID: 84937636735     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.05.019     Document Type: Article

References (35)

1. Palma D., Visser O., Lagerwaard F.J., Belderbos J., Slotman B.J., Senan S. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol 2010, 28:5153-5159.
2. Senthi S., Lagerwaard F.J., Haasbeek C.J., Slotman B.J., Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol 2012, 13:802-809.
3. Grills I.S., Mangona V.S., Welsh R., Chmielewski G., McInerney E., Martin S., et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol 2010, 28:928-935.
4. Bradley J.D., El Naqa I., Drzymala R.E., Trovo M., Jones G., Denning M.D. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant. Int J Radiat Oncol Biol Phys 2010, 77:1146-1150.
5. Khalaf M., Abdel-Nabi H., Baker J., Shao Y., Lamonica D., Gona J. Relation between nodule size and 18F-FDG-PET SUV for malignant and benign pulmonary nodules. J Hematol Oncol 2008, 1:13.
6. Vesselle H., Schmidt R.A., Pugsley J.M., Li M., Kohlmyer S.G., Vallires E., et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 2000, 6:3837-3844.
7. de Geus-Oei L.F., van Krieken J.H., Aliredjo R.P., Krabbe P.F., Frielink C., Verhagen A.F., et al. Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer 2007, 55:79-87.
8. Allibhai Z., Taremi M., Bezjak A., Brade A., Hope A.J., Sun A., et al. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2013, 87:1064-1070.
9. Berghmans T., Dusart M., Paesmans M., Hossein-Foucher C., Buvat I., Castaigne C., et al. European Lung Cancer Working Party for the ILCSP. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008, 3:6-12.
10. Paesmans M., Berghmans T., Dusart M., Garcia C., Hossein-Foucher C., Lafitte J.J., et al. European Lung Cancer Working P, on behalf of the ILCSP. Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. J Thorac Oncol 2010, 5:612-619.
11. Altman D.G., Lausen B., Sauerbrei W., Schumacher M. Dangers of using optimal cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994, 86:829-835.
12. Onishi H., Araki T., Shirato H., Nagata Y., Hiraoka M., Gomi K., et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 2004, 101:1623-1631.
13. Downey R.J., Akhurst T., Gonen M., Vincent A., Bains M.S., Larson S., et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 2004, 22:3255-3260.
14. Um S.W., Kim H., Koh W.J., Suh G.Y., Chung M.P., Kwon O.J., et al. Prognostic value of 18F-FDG uptake on positron emission tomography in patients with pathologic stage I non-small cell lung cancer. J Thorac Oncol 2009, 4:1331-1336.
15. Ohtsuka T., Nomori H., Watanabe K., Kaji M., Naruke T., Suemasu K., et al. Prognostic significance of [(18)F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma. Cancer 2006, 107:2468-2473.
16. Lin Y., Lin W.Y., Kao C.H., Yen K.Y., Chen S.W., Yeh J.J. Prognostic value of preoperative metabolic tumor volumes on PET-CT in predicting disease-free survival of patients with stage I non-small cell lung cancer. Anticancer Res 2012, 32:5087-5091.
17. Hanin F.X., Lonneux M., Cornet J., Noirhomme P., Coulon C., Distexhe J., et al. Prognostic value of FDG uptake in early stage non-small cell lung cancer. Eur J Cardiothorac Surg 2008, 33:819-823.
18. Raz D.J., Odisho A.Y., Franc B.L., Jablons D.M. Tumor fluoro-2-deoxy-d-glucose avidity on positron emission tomographic scan predicts mortality in patients with early-stage pure and mixed bronchioloalveolar carcinoma. J Thorac Cardiovasc Surg 2006, 132:1189-1195.
19. Goodgame B., Pillot G.A., Yang Z., Shriki J., Meyers B.F., Zoole J., et al. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer. J Thorac Oncol 2008, 3:130-134.
20. Dooms C., van Baardwijk A., Verbeken E., van Suylen R.J., Stroobants S., De Ruysscher D., et al. Association between 18F-fluoro-2-deoxy-d-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage non-small cell lung cancer. J Thorac Oncol 2009, 4:822-828.
21. Agarwal M., Brahmanday G., Bajaj S.K., Ravikrishnan K.P., Wong C.Y. Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ((18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC). Eur J Nucl Med Mol Imaging 2010, 37:691-698.
22. Burdick M.J., Stephans K.L., Reddy C.A., Djemil T., Srinivas S.M., Videtic G.M. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010, 78:1033-1039.
23. Clarke K., Taremi M., Dahele M., Freeman M., Fung S., Franks K., et al. Stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC): is FDG-PET a predictor of outcome. Radiother Oncol 2012, 104:62-66.
24. Hoopes D.J., Tann M., Fletcher J.W., Forquer J.A., Lin P.F., Lo S.S., et al. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer. Lung Cancer 2007, 56:229-234.
25. Nair V.J., MacRae R., Sirisegaram A., Pantarotto J.R. Pretreatment [18F]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early-stage non-small cell lung cancer treated with definitive radiation therapy: rethinking the role of positron emission tomography in personalizing treatment based on risk status. Int J Radiat Oncol Biol Phys 2014, 88:312-318.
26. Satoh Y., Nambu A., Onishi H., Sawada E., Tominaga L., Kuriyama K., et al. Value of dual time point F-18 FDG-PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy. Eur J Radiol 2012, 81:3530-3534.
27. Takeda A., Sanuki N., Fujii H., Yokosuka N., Nishimura S., Aoki Y., et al. Maximum standardized uptake value on FDG-PET is a strong predictor of overall and disease-free survival for non-small-cell lung cancer patients after stereotactic body radiotherapy. J Thorac Oncol 2014, 9:65-73.
28. Shultz D.B., Trakul N., Abelson J.A., Murphy J.D., Maxim P.G., Le Q.T., et al. Imaging features associated with disease progression after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer. Clin Lung Cancer 2014, 15:294-301. e293.
29. Abelson J.A., Murphy J.D., Trakul N., Bazan J.G., Maxim P.G., Graves E.E., et al. Metabolic imaging metrics correlate with survival in early stage lung cancer treated with stereotactic ablative radiotherapy. Lung Cancer 2012, 78:219-224.
30. Na F., Wang J., Li C., Deng L., Xue J., Lu Y. Primary tumor standardized uptake value measured on F18-Fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non-small-cell lung cancer receiving radiotherapy: meta-analysis. J Thorac Oncol 2014, 9:834-842.
31. Chang J.Y., Liu H., Balter P., Komaki R., Liao Z., Welsh J., et al. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Radiat Oncol 2012, 7:152.
32. Hamamoto Y., Sugawara Y., Inoue T., Kataoka M., Ochi T., Takahashi T., et al. Relationship between pretreatment FDG uptake and local control after stereotactic body radiotherapy in stage I non-small-cell lung cancer: the preliminary results. Jpn J Clin Oncol 2011, 41:543-547.
33. Takeda A., Yokosuka N., Ohashi T., Kunieda E., Fujii H., Aoki Y., et al. The maximum standardized uptake value (SUVmax) on FDG-PET is a strong predictor of local recurrence for localized non-small-cell lung cancer after stereotactic body radiotherapy (SBRT). Radiother Oncol 2011, 101:291-297.
34. Horne Z.D., Clump D.A., Vargo J.A., Shah S., Beriwal S., Burton S.A., et al. Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy. Radiat Oncol 2014, 9:41.
35. Kadota K., Colovos C., Suzuki K., Rizk N.P., Dunphy M.P., Zabor E.C., et al. FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma. Ann Surg Oncol 2012, 19:3598-3605.